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The major cause of mortality in breast cancer is the progression of
metastatic disease. Although loss of oestrogen receptors (ER) and
progesterone receptors is associated with more aggressive disease,
30% of patients with receptor-positive, node-negative tumours
develop metastases (Price et al, 1997). A component of the
metastatic process is invasion, which is accomplished when the
cells can transit the extracellular matrix (ECM) layer. More accu-
rate prognoses might be possible if factors could be identified that
either promote invasion or are markers for it, independent of
steroid receptor status. Specific treatments to prevent invasion
might also be developed.
Thrombin is a growth-regulatory protein at nanomolar concen-
trations. Thrombin is also a serine proteinase that is generally
associated with coagulation. Its proenzyme, prothrombin, occurs
in the plasma at concentrations up to 3 mM (Shapiro and McCord,
1978). Thrombin and its associated receptor, TR-1, are involved in
the activation of platelets (McNicol and Gerrard, 1993; Vittet and
Chevillard, 1993), growth stimulation of immature rat uterine
stromal cells (Arena et al, 1996), alteration of permeability in
vascular endothelial cells (DeMichele and Minnear, 1992; Garcia
et al, 1995), DNA synthesis in astrocytoma cells (Aragay et al,
1995) and endothelial cell growth in angiogenesis (Fidler and
Ellis, 1994). Thrombin also has been implicated in tumour
progression (Wojtukiewicz et al, 1995).
The initial step in characterization of thrombin￿s role in breast
tumour cell invasion is a description of the presence of TR-1 on inva-
sive breast tumour cell lines and of thrombin￿s influence on in vitro
invasion by those cell lines. We report the presence of TR-1 and
activity of thrombin in stimulating invasion by the MDA-MB231
breast cancer cell line and its absence in other, less aggressive, breast
tumour cell lines.
MATERIALS AND METHODS
Cell culture
Cells were cultured in Dulbecco￿s modified Eagle medium
(DMEM) without phenol red, with streptomycin, penicillin, non-
essential amino acids, glutamine and 5% serum (Hyclonedefined
calf serum for MDA-MB231 and MDA-MB436; Gibco fetal calf
serum for MCF-7 cells).
Conditioned medium was prepared by incubating confluent 3T3
cultures with bovine serum albumin (BSA) medium (DMEM
without phenol red, containing 0.1% BSA and antibiotics) for 24 h.
Conditioned medium was stored frozen and was centrifuged imme-
diately before use to remove cells and debris.
Invasion assays
Invasion chambers with 8-mm pores were purchased from
Becton—Dickinson. Chambers were used without modification for
chemotaxis assays. Matrigel-coated chambers were used for invasion
assays. Matrigel, purchased from Becton—Dickinson, was diluted in
ice-cold DMEM without additions. One hundred microlitres (38 mg)
was pipetted into each chamber in a 24-well plate. The plate was
incubated at 37°C for 1 h, then medium was removed by aspiration
and replaced with 400 ml of DMEM. Chambers were either used
immediately or after overnight storage at 4°C.
Assays were performed in 24-well plates. The wells contained
0.75 ml of either BSA medium (for blanks) or conditioned
medium. Inserts contained cells in BSA medium. Ten thousand
MDA-MB231 or MDA-MB436 cells, or 50 000 MCF-7 cells in
BSA medium with appropriate additions were placed in the inserts.
Media and cells were removed from the wells after 24 h at 37°C for
studies of invasion, or 6 h at 37°C for studies of chemotaxis,
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PO Box 509, Albany, NY 12201, USAleaving cells that had migrated on the underside of the membrane.
Membranes were stained with Diff Quik, dried and analysed with
the NIH Image program. About 20% of the total membrane area
was counted. Each experimental point had four replicates.
Flow cytometry
Cells were harvested for flow cytometry by scraping into BSA
medium plus protease inhibitors (aprotinin 1.6 U ml—1, soybean
trypsin inhibitor 2 mg ml—1, leupeptin 2 mg ml—1, pepstatin
7 mg ml—1, antipain 37 mg ml—1, bestatin 0.1 mg ml—1). Cells were
washed once with the same medium, counted, washed with phos-
phate buffered saline—0.1% azide (PBSA), and diluted for assay in
PBSA. Aliquots of 106 cells were incubated with primary anti-
body, washed twice with PBSA, incubated with FITC-labelled
goat anti-mouse (IgG and IgM) (Boehringer—Mannhein), washed
twice and analysed in a FACScan instrument (Becton—Dickinson).
The primary antibody, PF-11, is a monoclonal raised against a
peptide containing residues 29—69 of the human TR-1 (Kranzhofer
et al, 1996), which includes the thrombin binding site and the
anion-binding exosite of TR-1. It was generously provided by
Dr Shaun Coughlin, UCSF. A mouse IgG, 2b (Sigma), was the
isotype control.
Stable transfection with pHEO
MDA-MB231 cells were stably transfected with pHEO to form the
oestrogen receptor-positive cell line MDAL3, as previously
described (Tora et al, 1989; Pentecost, 1998).
Statistics
Results are presented as means ± s.e.m. Data were analysed by
Student￿s two tailed test or by ANOVA with the Student—
Newman—Keuls post test for differences among groups.
RESULTS
Thrombin-stimulated invasion through Matrigel
The three cell lines have been characterized in the literature as
highly invasive (MDA-MB231), moderately invasive (MDA-
MB436), and minimally invasive (MCF-7) (Thompson et al, 1992).
The relative invasiveness of the cell lines was confirmed as shown
in Figure 1. The extent of thrombin-stimulated invasion is given
relative to control values. The broad differences in the number of
migratory cells in control samples, 51 for MCF-7 cells, 217 for
MDA-MB436 cells, and 317 for MDA-MB231 cells, emphasize
the very different inherent invasive capacities of these cell lines on
a Matrigel matrix. The effect of 100 nM thrombin on invasion is
also given. Thrombin stimulated invasion in the MDA-MB231 cell
line, but did not stimulate MDA-MB436 or MCF-7 cells.
Thrombin is a stimulator of movement, not a chemoattractant,
in invasion assays. The chemoattractant is the 3T3-conditioned
medium in the well, whereas the thrombin is placed in the insert
with the cells.
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Figure 1 Modulation of invasion by cell lines upon treatment with 100 nM
thrombin. Six to nine independent experiments were performed with each cell
line; four replicates of each treatment were carried out. In the controls, the
actual mean number of invading cells (± s.e.m.) was 317 ± 136 for MDA-
MB231 cells, 51 ± 9 for MCF-7 cells, and 217 ± 119 for MDA-MB436 cells.
For comparative purposes, the number of invading cells in the controls was
restated as 1.0 (± relative s.e.m.). Invasion of thrombin-treated cells is given
relative to controls. By Student’s t test, P = 0.004 for stimulation of invasion
of MDA-MB231 cells by thrombin; thrombin does not significantly stimulate
the other cell lines
Figure 3 Effects of hirudin and TRAP on invasion by MDA-MB231 cells.
Thrombin (100 nM), 50 mM TRAP, and 140 nM hirudin were used. Each bar
represents the sum of at least two independent experiments with three or
four replicates of each point. The actual number of invading cells in the
control was 210 ± 114. Thrombin and TRAP both significantly increased
invasion, P < 0.001 compared with control for each
Figure 2 Concentration dependence of stimulation of invasion by thrombin.
Each line represents the sum of two experiments with four replicates of each
point. The mean number of cells invading in the control samples was: MDA-
MB231 cells, 501 ± 217; MDA-MB436 cells, 750 ± 160; MCF-7 cells, 79 ± 26The concentration dependence of thrombin stimulation is shown
in Figure 2. Data are reported relative to invasion by the unstimu-
lated cell cultures. MDA-MB231 cells were stimulated by all
concentrations above 0.1 nM. MDA-MB436 cells and MCF-7 cells
were not stimulated by any concentration of thrombin, up to
100 nM. Thrombin had no effect on the viability of the cell lines
(data not shown).
Actions of thrombin can be inhibited by hirudin, a highly specific
inhibitor of proteolysis by thrombin. Effects that occur through the
thrombin receptor, TR-1, require enzymatically active thrombin and
can be elicited by thrombin receptor activating peptide (TRAP).
Thrombin-stimulated invasion by MDA-MB231 cells, shown in
Figure 3, was completely eliminated by a slight molar excess of
hirudin (140 nM hirudin and 100 nM thrombin), whereas hirudin
alone had no effect. Similar results (not shown) were obtained with
thrombin inactivated with the highly specific thrombin inhibitor,
Pro—Phe—Arg chloromethyl ketone (PPACK). Stimulation of inva-
sion by 50 mM TRAP, also shown in Figure 3, demonstrated the role
of TR-1 in thrombin action. No stimulation occurred with an
unrelated peptide, TCHDVLNETLLHG, not shown.
Effect of thrombin on chemotaxis
Movement of cells through the uncoated membrane of an invasion
chamber (chemotaxis) is a measure of cell motility, independent of
attachment to or digestion of ECM. Figure 4 shows that 100 nM
thrombin had no effect on chemotaxis except in MCF-7 cells
where it increased the number of migrating cells from 25 to 30.
The absence of a TR-1-mediated effect on chemotaxis was
confirmed by experiments with TRAP. At 50 mM, TRAP had no
effect on chemotaxis for any of the three cell lines, as shown in
Figure 5.
A failure of thrombin to stimulate chemotaxis would result if the
thrombin diffused through the open pores of the invasion chamber
and digested the chemoattractant in the well. To eliminate that
possibility, 3T3-conditioned medium was pretreated with
thrombin and the excess thrombin was inactivated with PPACK.
The treated media were then used as the chemoattractant for
invasion assays with MDA-MB231 cells. If thrombin digested
the chemotaxin, the treated media would not stimulate invasion.
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Figure 6 Detection of TR-1 on cell lines by flow cytometry. Cells were
labelled as described in the Materials and methods section and analysed by
FACScan. Typical scans are shown for MDA-MB436 cells (A), MCF-7 cells
(B), and MDA-MB231 cells (C). The relative fluorescence intensity when
cells were labelled with the isotype control is given by the open line. The
solid peak gives the relative fluorescence intensity of the cells labelled with
antibody to TR-1. Only for MDA-MB231 cells was there a difference between
the two peaks
Figure 4 Chemotaxis by cell lines with 100 nM thrombin. Four or five
independent experiments were carried out with each cell line, with four
replicates of each treatment. The actual mean number of stained cells in the
controls was 752 ± 81 for MDA-MB231, 25 ± 7 for MCF-7, and 165 ± 61 for
MDA-MB436 cells. The control and thrombin values are not statistically
different except for MCF-7 cells, in which thrombin stimulated chemotaxis
from 25 cells to 30, P = 0.036
Figure 5 Chemotaxis and TRAP. Two or three independent experiments
were carried out with each cell line, with four replicates of control samples
and four to six replicates of TRAP samples. The actual mean number of
stained cells in the controls was 1068 ± 160 for MDA-MB231 cells, 138 ± 32
for MDA-MB436 cells, and 18 ± 1.8 for MCF-7 cells. There was no effect of
50 mM TRAP on chemotaxisMedia treated with thrombin and PPACK or PPACK only stim-
ulated 50% of the invasion stimulated by control media. Addition
of thrombin to the cells (50 nM) resulted in a two- to threefold
stimulation of invasion. The absence of an effect of thrombin on
chemotaxis cannot be attributed to destruction of the chemotaxin.
TR-1 on cell surfaces
To demonstrate TR-1 on the surface of the three cell lines, cells
were harvested by scraping, labelled with monoclonal antibody
PF-11 for TR-1, and analysed by flow cytometry. The results of a
typical determination are shown in Figure 6. For both MCF-7 and
MDA-MB436 cells, the PF-11-labelled peak coincided with the
isotype control, indicating the absence of detectable TR-1 on the
surface of these cell lines. The MDA-MB231 cells had a slightly
shifted peak with PF-11, indicating the presence of TR-1 on these
cells. Because the differences between control and PF-11-treated
cells were small, these experiments were repeated five to seven
times with duplicate samples. Averaged data, shown in Table 1,
were subjected to statistical analysis, which gives validity to the
detection of TR-1 on MDA-MB231 cells.
Oestrogen receptor and TR-1 expression
To investigate whether a link exists between oestrogen and TR-1,
the MDAL3 cell line, derived from MDA-MB231 cells by stable
transfection with the pHEO oestrogen receptor construct (Tora et al,
1989; Pentecost, 1998), was used. Cells were grown with or without
10 nM oestradiol for 5—7 days until confluence was reached. TR-1
was assayed by flow cytometry. As shown in Table 2, TR-1 was
present in the MDAL3 cells; there was no difference in the amount
of TR-1 detected in the cells whether oestradiol was present or not.
DISCUSSION
Thrombin has long been thought to play a role in cancer biology.
Activation of coagulation in cancer patients was first observed in
1865 (Wojtukiewicz et al, 1993); in the 1930s, it was suggested
that coagulation factors might contribute to tumour growth
(Zacharski, 1996). Anti-thrombotic therapy with warfarin or with
heparin has been beneficial in the treatment of small-cell lung
carcinoma (Zacharski et al, 1992; Zacharski and Costantini, 1995).
Understanding of the cellular role of thrombin in tumour
biology is incomplete. Zacharski et al (1995) have demonstrated
the presence of thrombin by immunohistochemistry on cells of
small-cell lung carcinoma, renal carcinoma and melanoma.
Nierodzik et al (1996) demonstrated the presence of TR-1 on the
surface of six (non-breast) tumour cell lines and showed that
receptor activation increased platelet adhesion and tumour
tyrosine phosphorylation. Wojtukiewicz et al (1993) showed that
thrombin enhanced tumour cell adhesion to endothelial cells and
to fibronectin, a process vital for metastasis to occur.
In vitro invasion, assayed by movement of cells through a layer
of ECM, provides a good experimental system to study this
component of metastasis. Although the results do not correlate
precisely with metastatic potential in vivo, these assays are a good
measure of tumour aggressiveness (Thompson et al, 1992; Azzam
et al, 1993).
The results reported here show clearly that thrombin potentiates
invasion in a breast tumour cell line through an action of its
receptor, TR-1. TR-1 is a 7-transmembrane-domain receptor,
coupled to Gi and to Gq. Stimulation of a cell by thrombin has many
effects including: stimulation of phospholipases C, A2 and D; an
increase in cytosolic free Ca++; activation of protein kinase C, MAP
kinases and tyrosine kinases; suppression of cAMP synthesis; stim-
ulation of mitogenesis (Brass, 1995; Brass et al, 1997).
Thrombin is not a chemoattractant in the experiments reported
here. Instead, it is a stimulator of invasion because it is added
directly to the cells in the invasion chamber. Of the three cell lines,
only the MDA-MB231 cells have detectable TR-1 on their surface,
and only MDA-MB231 cells respond to thrombin with increased
invasion. Thrombin has no effect on chemotaxis with MDA-
MB231 cells, so alterations in motility (the capacity of the cells to
move) can be ruled out as the mechanism of the thrombin effect.
Thrombin does stimulate motility of the MCF-7 cell line, despite
the absence of detectable TR-1 on these cells. MCF-7 may have a
very low level of TR-1 (undetectable by flow cytometry), or it may
respond to thrombin through one of the other protease-activated
receptors. For the stimulation of chemotaxis to occur without stim-
ulation of invasion indicates that MCF-7 has little or no ability to
digest ECM and permit cell movement.
Expression of TR-1 in these cell lines is independent of ER.
Transfection of MDA-MB231 with pHEO (to give MDAL3) did
not affect expression of TR-1; the level of TR-1 in MDAL3 cells
was not statistically different from that of the parental cells.
Expression in MDAL3 cells was not affected by oestradiol in the
growth medium. We did find that cell number in the presence of
oestradiol was reduced to 70% of the value in the absence of
oestradiol. Thus, we confirmed the observation from Rochefort￿s
laboratory (Garcia et al, 1997) that oestrogen slows the growth of
the transfected cells.
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Table 1 Flow cytometry for TR-1 on breast tumour cell lines. The indicated
number of samples was analysed in five to seven independent experiments.
Data are given as means ± s.e.m. Isotype control and TR-1 antibody (PF-11)
were used at the same protein concentration
Cell line Sample Relative fluorescence Ratio P-value
number intensity PF-11/control
MDA-MB231 14 Control 3.85 ± 1.08 1.45 ± 0.31 <0.001
PF-11 5.52 ± 0.66
MDA-MB436 10 Control 6.41 ± 2.10 1.05 ± 0.26 0.57
PF-11 7.00 ± 3.69
MCF-7 13 Control 5.77 ± 1.18 0.98 ± 0.22 0.79
PF-11 5.52 ± 1.07
Table 2 Flow cytometry for TR-1 on MDA-MB231 cells transfected with
oestrogen receptor (MDAL3 cells). The indicated number of samples was
analysed in two independent experiments. Data are given as means ± s.e.m.
Cells were grown to confluence in the presence or absence of 10 nM
oestradiol for 5–7 days. Fresh oestradiol was added two or three times, with
each change of medium
Cell treatment Sample Ratio P-value
number PF-11/control
No oestradiol 14 1.26 ± 0.05 <0.001 compared with control
Oestradiol (10–9 M) 4 1.17 ± 0.05 <0.001 compared with control
P = 0.08 (not significant)
compared with cells grown
without oestradiolWhatever thrombin￿s involvement is in tumour invasion, it
occurs through TR-1 because the thrombin effects also occur after
TRAP stimulation of the cells. Thus, direct activation by thrombin
of matrix metalloproteinases (MMPs) or tissue plasminogen acti-
vator is not consistent with our results.
A key question then is whether thrombin and TR-1 can be
implicated in invasion through altered expression of MMPs and/or
integrins.
MMPs and their role in cancer have been objects of intense
research; stromelysin 3 expression (Chenard et al, 1996) and
MMP-2 (gelatinase A) activation (Azzam et al, 1993; Bae et al,
1993; Thompson et al, 1994) are associated with increased inva-
sion by breast cancer cell lines. Thrombin effects on MMPs have
been studied in vascular cells; thrombin activates pre-existing
MMP-2 in vascular endothelial and smooth muscle cells (Zucker
et al, 1995; Galis et al, 1997). Evidence for the induction of
expression of MMPs by thrombin is not extensive: in vascular
endothelial cells, MMP-3 (but not MMP-2) is induced by thrombin
(Duhamel-Clerin et al, 1997).
Integrins are cell-surface receptors for ECMs. Alteration in their
expression as tumours progress has also been an intensely studied
field. The integrin a2b1, which is widely expressed on breast
tumour cells, is a receptor for collagen and laminin in less aggres-
sive breast tumour cell lines, but loses its laminin receptor function
in more aggressive cell lines such as MDA-MB231 (Maemura et
al, 1995). A connection has been made between TR-1 and integrin
expression in human colon cancer, rat carcinosarcoma and mouse
melanoma (Wojtukiewicz et al, 1995). In these cells, thrombin or
the TRAP peptide stimulated cell adhesion to fibronectin. Because
integrin a3b1 is a fibronectin receptor (Gui et al, 1997), these
results suggest that increased expression of an integrin could result
from activation of TR-1.
Thrombin and its receptor, TR-1, are implicated in stimulating
invasive activity in MDA-MB231 breast cancer cells. TR-1
expression and thrombin activity appear to be independent of
oestrogen receptor expression. TR-1 expression might serve as a
prognostic indicator, independent of ER status, of aggressive,
invasive breast cancer.
ACKNOWLEDGEMENTS
This work was aided by the staff and resources of the Wadsworth
Center core facilities for cell culture, peptide synthesis, molecular
genetics, and molecular immunology. We thank Dr Abigail
Snyder-Keller for providing the microscope and NIH Image
program for analysis of the data and Dr David Spink for the gift of
the MDA-MB436 cell line.
NOTE ADDED IN PROOF
While this paper was under review, S. Even-Ram et al published a
paper with similar conclusions: Even-Ram S, Vziely B, Cohen P,
Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I
and Bar-Shavit R (1998) Thrombin receptor overexpression in
malignant and physiological invasion processes. Nature Medicine
4: 909—913.
REFERENCES
Aragay AM, Collins LR, Post GR, Watson AJ, Feramisco JR, Brown JH and
Simon MI (1995) G12 requirement for thrombin-stimulated gene expression
and DNA synthesis in 1321N1 astrocytoma cells. J Biol Chem 270:
20073—20077
Arena C, Quirk SM, Zhang YQ and Henrikson KP (1996) Rat uterine stromal cells:
thrombin receptor and growth stimulation by thrombin. Endocrinology 137:
3744—3749
Azzam HS, Arand G, Lippman ME and Thompson EW (1993) Association of MMP-
2 activation potential with metastatic progression in human breast cancer cell
lines independent of MMP-2 production. J Natl Cancer Inst 85: 1758—1764
Bae SN, Arand G, Azzam HS, Pavasant P, Torri J, Frandsen TL and Thompson EW
(1993) Molecular and cellular analysis of basement membrane invasion by
human breast cancer cells in Matrigel-based in vitro assays. Breast Cancer Res
Treat 24: 241—255
Brass LF (1995) Issues in the development of thrombin receptor antagonists. Thromb
Haemost 74: 499—505
Brass LF, Manning DR, Cichowski K and Abrams CS (1997) Signaling through G
proteins in platelets: to the integrins and beyond. Thromb Haemost 78: 581—589
Chenard MP, O￿Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq
JP and Duffy MJ (1996) High levels of stromelysin-3 correlate with poor
prognosis in patients with breast carcinoma. Int J Cancer 69: 448—451
DeMichele MAA and Minnear FL (1992) Modulation of vascular endothelial
permeability by thrombin. Semin Thromb Hemost 18: 287—295
Duhamel-Clerin E, Orvain C, Lanza F, Cazenave JP and Klein-Soyer C (1997)
Thrombin-receptor mediated increase of two matrix metalloproteinases, MMP-
1 and MMP-3, in human endothelial cells. Arterioscler Thromb Vasc Biol 17:
1931—1938
Fidler IJ and Ellis LM (1994) The implications of angiogenesis for the biology and
therapy of cancer metastasis. Cell 79: 185—188
Galis ZS, Kranzhofer R, Fenton II JW and Libby P (1997) Thrombin promotes
activation of matrix metalloproteinase-2 produced by cultured vascular smooth
muscle cells. Arterioscler Thromb Vasc Biol 17: 483—489
Garcia JGN, Pavalko FM and Patterson CE (1995) Vascular endothelial cell
activation and permeability responses to thrombin. Blood Coag Fibrinol 6:
609—626
Garcia M, Derocq D, Platet N, Bonnet S, Brouillet JP, Touitou I and Rochefort H
(1997) Both estradiol and tamoxifen decrease proliferation and invasiveness of
cancer cells transfected with a mutated estrogen receptor. J Steroid Biochem
Mol Biol 61: 11—17
Gui GPH, Puddefoot JR, Vinson GP, Wells CA and Carpenter R (1997) Altered cell-
matrix contact: a prerequisite for breast cancer metastasis? Br J Cancer 75:
623—633
Kranzhofer R, Clinton SK, Ishii K, Coughlin SR, Fenton II JW and Libby P (1996)
Thrombin potently stimulates cytokine production in human vascular smooth
muscle cells but not in mononuclear phagocytes. Circ Res 79: 286—294
Maemura M, Akiyama SK, Woods Jr VL and Dickson RB (1995) Expression and
ligand binding of a2b1 integrin on breast carcinoma cells. Clin Exp Metastasis
13: 223—235
McNicol A and Gerrard JM (1993) Post-receptor events associated with thrombin-
induced platelet activation. Blood Coag Fibrinol 4: 975—991
Nierodzok ML, Bain RM, Liu LX, Shivji M, Takeshita K and Karpatkin S (1996)
Presence of the seven transmembrane thrombin receptor on human tumor cells:
effect of activation on tumor adhesion to platelets and tumor tyrosine
phosphorylation. Br J Haematol 92: 452—457
Pentecost BT (1998) Expression and estrogen regulation of the HEM45 mRNA in
human tumor lines and in the rat uterus. J Steroid Biochem Mol Biol 63: 1—9
Price JT, Bonovich MT and Kohn EC (1997) The biochemistry of cancer
dissemination. CRC Crit Rev Biochem Mol Biol 32: 175—253
Shapiro SS and McCord S (1978) Prothrombin. In Progress in Hemostasis and
Thrombosis, vol. 4, p. 177. Grune & Stratton, New York
Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB,
Torri J, Donahue S, Lippman ME, Martin GR and Dickson RB (1992)
Association of increased basement membrane invasiveness with the absence of
estrogen receptor and expression of vimentin in human breast cancer cell lines.
J Cell Physiol 150: 534—544
Thompson EW, Yu M, Bueno J, Jin L, Maiti SN, Palao-Marco FL, Pulyaeva H,
Tamborlane JW, Tirgari R and Wapnir I (1994) Collagen-induced MMP-2
activation in human breast cancer. Breast Cancer Res Treat 31: 357—370
Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I and Chambon P (1989)
The cloned human estrogen receptor contains a mutation which alters its
hormone binding properties. EMBO J 8: 1981—1986
Vittet D and Chevillard C (1993) Thrombin interactions with cells of the
megakaryocytic lineage. Blood Coag Fibrinol 4: 759—768
Wojtukiewicz MZ, Tang DG, Ciarelli JJ, Nelson KK, Walz DA, Diglio CA,
Mammen EF and Honn KV (1993) Thrombin increases the metastatic potential
of tumor cells. Int J Cancer 54: 793—806
Thrombin and breast cancer invasiveness 405
British Journal of Cancer (1999) 79(3/4), 401–406 © Cancer Research Campaign 1999Wojtukiewicz MZ, Tang DG, Ben-Josef E, Renaud C, Walz DA and Honn KV
(1995) Solid tumor cells express functional ￿tethered ligand￿ thrombin receptor.
Cancer Res 55: 698—704
Zacharski LR (1996) Blood coagulation factors in tumor tissue: implications for
cancer therapy. In Malignome und Haemostase. Spanuth E (ed.), p. 134.
Springer Verlag: Berlin
Zacharski LR and Costantini V (1995) Blood coagulation activation in cancer:
challenges for cancer treatment. Hamostaseologie 15: 14—20
Zacharski LR, Wojtukiewicz ME, Costantini V, Ornstein DL and Memoli VA (1992)
Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb
Hemost 18: 104—116
Zacharski LR, Memoli VA, Morain WD, Schaeppl JM and Rousseau SM (1995)
Cellular localization of enzymatically active thrombin in intact human tissues
by hirudin binding. Thromb Haemost 73: 793—797
Zucker S, Conner C, DiMassmo BI, Ende H, Drews M, Seiki M and Bahou WF
(1995) Thrombin induces the activation of progelatinase A in vascular
endothelial cells. J Biol Chem 270: 23730—23738
406 KP Henrikson et al
British Journal of Cancer (1999) 79(3/4), 401–406 © Cancer Research Campaign 1999